tbuckley/cabot-search huggingface dataset:
Abstract 18549: Effects of AMR101, a Pure Eicosapentaenoic Omega-3 Fatty Acid, on the Fatty Acid Profile in Plasma and Red Blood Cells in Statin-Treated Patients With Persistent High Triglycerides (Results from the ANCHOR Study)
Authors: Rene Braeckman, Mehar S Manku, Christie M Ballantyne, William G Stirtan, Paresh N Soni
Journal: Circulation (2012)

AMR101 is an omega-3 fatty acid (FA) investigational new drug containing ≥96% pure icosapent ethyl, the ethyl ester of eicosapentaenoic acid (EPA). This subanalysis of the ANCHOR study evaluated the effects of AMR101 on the FA profiles and relationships between AMR101 and triglyceride (TG) lowering in plasma and RBCs. ANCHOR was a phase 3, double-blind, 12-week clinical study in high-risk statin-treated patients with residually high TG levels (≥200 and &lt;500 mg/dL) despite LDL cholesterol control (≥40 and &lt;100 mg/dL). Patients (N=702) on stable diet were randomized to AMR101 4 g/d, 2 g/d, or placebo. Twenty eight FAs were measured in plasma and RBCs for 153 patients using a gas chromatography/flame ionization detection method. Mean baseline plasma EPA levels were 20, 27, and 24 μg/g for AMR101 4 g/d, 2 g/d, and placebo, respectively; Mean placebo-adjusted EPA levels increased by 650% (P&lt;0.0001) and 268% (P&lt;0.0001) with AMR101 4 g/d and 2 g/d by week 12. Mean baseline plasma EPA expressed as percentage of total FAs (mol%) was 0.4, 0.5, and 0.5% for AMR101 4 g/d, 2 g/d, and placebo, respectively. Mean plasma EPA (mol%) at Week 12 was 3.6, 1.9, and 0.5% for AMR101 4 g/d, 2 g/d, and placebo, respectively. Levels of the EPA metabolite omega-3 docosapentaenoic acid also increased with both doses of AMR101 (P&lt;0.0001). The arachidonic acid (AA)/EPA plasma ratio has been suggested to be useful as a biomarker for arteriosclerotic disease. Mean placebo-adjusted AA/EPA plasma ratio decreased from baseline by 90% (P&lt;0.0001) and 75% (P&lt;0.0001) with AMR101 4 g/d and 2 g/d. Total omega-3 FAs increased and total omega-6 FAs decreased with both doses of AMR101 (P&lt;0.0001). Similar results were observed in RBCs. Increased doses of AMR101 resulted in increased EPA levels and corresponded with reductions in TG. The TG-lowering effect of AMR101 was due to the increase in EPA, as there were no statistically significant changes in plasma docosahexaenoic acid concentrations. Overall, AMR101 significantly increased EPA in plasma and RBCs in a linear, dose-dependent fashion consistent with its TG-lowering effect and caused other shifts in FA concentration and RBC membrane content that may have clinical benefit.
The role of Risk of Malignancy Index (RMI) based on serum CA-125 level, ultrasound score and menopausal status in pre-operative evaluation of adnexal mass
Authors: J. Pariyar
Journal: Journal of Clinical Oncology (2008)

16578 Background: The pre-operative knowledge regarding the nature of adnexal mass is necessary so that optimal surgery can be planned at the time of initial treatment. Tumour markers and/or radiological investigations are usually done for evaluating the nature of adnexal mass - benign or malignant. This study done to determine the role of Risk of Malignancy Index (RMI) based on serum CA-125 level, Ultrasound Score and Menopausal Status in diagnosing the nature of adnexal mass is presented here. Design: Cross-sectional. Methods: 70 patients with undiagnosed adnexal mass, admitted in one year (15 May, 2005 - 14 May, 2006) in gynaecology ward of TU Teaching Hospital, Kathmandu, Nepal for surgery were taken for study. The sensitivity, specificity, positive and negative predictive values of serum CA-125, ultrasound score and menopausal status were evaluated separately and in combination form RMI ( RMI = U X M X Serum CA- 125). Results: Among 70 cases, 20 (28.6%) had malignancy out of which 19 (95%) were primary ovarian carcinoma. 80% (n=16) of the ovarian cancer was in advanced stage and serous cystadenocarcicoma -55% (n=11) was the commonest histopathology. The mean age of patients with malignant ovarian tumour was 45.2 years and that with benign tumour was 34.6 years. Post-menopausal women were 7 times more likely to have ovarian malignancy as compared to menstruating women (OR - 7.33). In univariate analysis, the best performance was obtained in serum CA-125 at cut-off level 100 U/ml (sensitivity 85%, specificity 94%), followed by ultrasound score at cut-off score of 2 (sensitivity 50%, specificity 88%). The performance obtained for the risk of malignancy index (RMI) at cut-off level of 200 was - sensitivity 85% for both RMI-1 and RMI-2, whereas specificity of RMI-1 was higher than RMI-2 at 94% and 88% respectively. Conclusion: Risk of Malignancy Index (RMI) is a simple, valuable and highly reliable in pre-operative differentiation of the nature of adnexal mass. It can be clinically applicable in a resource constraint country like Nepal. No significant financial relationships to disclose.
Trastuzumab/At-101 Combination Induces Apoptosis and Shows Synergistic Cytotoxicity in Her2-Positive Breast Cancer Cells By Inhibition of Pi3K Signaling: a Novel Combination to Overcome Resistance to Anti-Her2 Therapy
Authors: B.S. Karaca, Z. Surmeli, P. Gursoy, A.P. Erdogan, U.A. Sanli, R. Uslu
Journal: Annals of Oncology (2014)
Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors
Authors: Corinne Couteau, Marie-Laure Risse, Michel Ducreux, Florence Lefresne-Soulas, Alessandro Riva, Anne Lebecq, Pierre Ruffié, Philippe Rougier, François Lokiec, René Bruno, Jean-Pierre Armand
Journal: Journal of Clinical Oncology (2000)

PURPOSE: We conducted a phase I and pharmacokinetic study of docetaxel in combination with irinotecan to determine the dose-limiting toxicity (DLT), the maximum-tolerated dose (MTD), and the dose at which at least 50% of the patients experienced a DLT during the first cycle, and to evaluate the safety and pharmacokinetic profiles in patients with advanced solid tumors. PATIENTS AND METHODS: Patients with only one prior chemotherapy treatment (without taxanes or topoisomerase I inhibitors) for advanced disease were included in the study. Docetaxel was administered as a 1-hour IV infusion after premedication with corticosteroids followed immediately by irinotecan as a 90-minute IV infusion, every 3 weeks. No hematologic growth factors were allowed. RESULTS: Forty patients were entered through the following seven dose levels (docetaxel/irinotecan): 40/140 mg/m 2 , 50/175 mg/m 2 , 60/210 mg/m 2 , 60/250 mg/m 2 , 60/275 mg/m 2 , 60/300 mg/m 2 , and 70/250 mg/m 2 . Two hundred cycles were administered. Two MTDs were determined, 70/250 mg/m 2 and 60/300 mg/m 2 ; the DLTs were febrile neutropenia and diarrhea. Neutropenia was the main hematologic toxicity, with 85% of patients experiencing grade 4 neutropenia. Grade 3/4 nonhematologic toxicities in patients included late diarrhea (7.5%), asthenia (15.0%), febrile neutropenia (22.5%), infection (7.5%), and nausea (5.0%). Pharmacokinetics of both docetaxel and irinotecan were not modified with the administration schedule of this study. CONCLUSION: The recommended dose of docetaxel in combination with irinotecan is 60/275 mg/m 2 , respectively. At this dose level, the safety profile is manageable. The activity of this combination should be evaluated in phase II studies in different tumor types.
Natural Killer Cell–Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future
Authors: Aura Muntasell, Miguel López-Botet
Journal: Clinical Cancer Research (2016)

Abstract The article by Curti and colleagues highlights the potential of natural killer (NK) cell–based adoptive cellular immunotherapy in oncology, currently boosted by advances in the knowledge on NK cell biology and in their ex vivo GMP manipulation. Several issues deserve attention to fully achieve the translation of these advances to the clinic. Clin Cancer Res; 22(8); 1831–3. ©2016 AACR. See related article by Curti et al., p. 1914
Cost of breast cancer treatment and follow-up care in Medicaid beneficiaries: Implications for state programs providing coverage for low-income women.
Authors: D. U. Ekwueme, S. Sujha, J. Trogdon
Journal: Journal of Clinical Oncology (2010)

e12000 Background: In the United States, breast cancer imposes a considerable health and economic burden to society as well as to individuals, particularly to low-income women. In 2000, the U.S. Congress passed the Breast and Cervical Cancer Prevention and Treatment Act to give states the opportunity to provide medical assistance through Medicaid for women who were screened for and found to have breast cancer through the CDC's National Breast and Cervical Cancer Early Detection Program.To date, no study has reported on the cost of treating breast cancer among Medicaid beneficiaries aged < 65 years. This study assesses the incremental cost of breast cancer care among low-income women < 65 years of age eligible for Medicaid program in North Carolina (NC). Methods: Administrative data from the NC Medicaid program linked with cancer registry data were analyzed to derive monthly Medicaid costs for cancer patients and the incremental costs of breast cancer care at 6, 12 and 24 months from diagnosis. We compared 848 beneficiaries diagnosed with cancer during the years 2002 to 2004 with 1,696 controls matched on age. We used a two-part regression model to predict the impact of breast cancer diagnosis by stage. Results: The incremental costs (std error) of treating breast cancer relative to no cancer at 6 months after diagnosis were $11,350 ($760), $20,227 ($1,146), and $28,911 ($3,422) for those with local, regional and distant breast cancers, respectively. These costs increased 33.0%, 43.7%, and 50.6% at 12 months; and 39.3, 45.4, and 73.6% at 24 months, respectfully. Average monthly costs for those with local and regional cancers declined to the levels of non-cancer beneficiaries by 9 and 15 months respectively, while those with distant cancers remained higher through 24 months. Conclusions: The observed extended period of health care utilization, beyond the immediate 6-month period after diagnosis, indicates that Medicaid coverage may be required for many months after diagnosis to ensure the provision of adequate care. Late stage cancers may require more treatment and follow-up procedures; therefore, early detection of breast cancer could be expected to reduce the costs incurred by Medicaid. No significant financial relationships to disclose.
Early indoor aeroallergen exposure is not associated with development of sensitization or allergic rhinitis in high-risk children
Authors: A.-M. M. Schoos, B. L. Chawes, E. Jelding-Dannemand, L. B. Elfman, H. Bisgaard
Journal: Allergy (2016)

Rationale Allergen exposure is associated with the development of allergic sensitization in childhood as reflected by global variations in sensitization patterns. However, there is little evidence to support a direct association. Objectives To investigate the association between perinatal aeroallergen exposure and sensitization and rhinitis to such allergens later in childhood. Methods Allergic sensitization to cat, dog, and house dust mites was diagnosed longitudinally using skin prick tests and specific IgE measurements at ½, 1½, 4, 6, and 13 years in 399 children from the Copenhagen Prospective Study on Asthma in Childhood2000 birth cohort. Rhinitis was diagnosed at 7 and 13 years. Allergen exposure was defined as dog or cat in the home during the 3rd trimester of pregnancy or the first year of life and as allergen levels of dog, cat, and house dust mite in bed dust samples at 1 year. Associations between exposure and outcomes were analyzed by logistic regression and stratified for eczema status and test method (skin prick test and specific IgE). Results We found no association between dog or cat exposure in perinatal life and sensitization or rhinitis during childhood. Similarly, there was no association between levels of allergens in bed dust samples and sensitization or rhinitis during childhood. Conclusion Perinatal indoor aeroallergen exposure does not seem to affect development of allergic sensitization or rhinitis during childhood questioning the relevance of allergen avoidance as a preventive measure. Other factors such as timing of allergen exposure or other environmental adjuvants may contribute in a more complex pathway to sensitization.
Morphologic assessment of peripheral blood smears in patients with circulating tumor cells (CTCs)
Authors: K. Bethel, R. Scuderi, D. Marrinucci, J. M. Fisher, N. Lazarus, D. Lazar, P. Kuhn
Journal: Journal of Clinical Oncology (2008)

1137 Background: We recently described a novel method for detecting circulating tumor cells (CTCs) in peripheral blood using indirect immunofluorescence for epithelial-derived cells in conjunction with fiber-optic array scanning technology (FAST). The current study was designed to assess microscopic features on peripheral blood smears in metastatic cancer patients with CTCs to see if any morphologic parameters were affected. Methods: Wright-Giemsa stained smears of EDTA-anti-coagulated peripheral blood were prepared and assessed microscopically at 40x and 100x (using oil immersion). Parameters studied included differential white blood cell count, proportions of lymphocyte subsets, grade of neutrophil and monocyte activation, and the presence or absence of rouleaux formation, platelet satellitosis and platelet clumping. Three groups were studied: normal healthy donors (n=8), metastatic tumor patients without detectable CTCs (n=10), and metastatic tumor patients with detectable CTCs (n=12). Results: A trend towards increased neutrophilia and decreased lymphocytosis (with increased proportions of activated and large granular lymphocytes) was observed in metastatic tumor patients with detectable CTCs versus tumor patients without detectable CTCs. Other features such as platelet clumping, rouleaux formation, and monocyte activation were occasionally observed, but did not vary significantly between the three groups. Platelet satellitosis was only observed in one sample, from a patient with undetectable CTCs. Conclusions: EDTA-induced platelet clumping/satellitosis is not increased in patients with CTCs. However, an increased proportion of activated and large granular lymphocytes was observed in patients with metastatic disease and detectable CTCs as compared to patients with metastatic disease and no detectable CTCs. Further studies using flow cytometry may be helpful to objectively characterize lymphocyte subsets (e.g. CD4, CD8) in patients with CTCs. These and other studies will help to delineate whether altered lymphocyte subset profiles reflect a T-cell response to CTCs and, if so, whether these have prognostic and/or therapeutic value. No significant financial relationships to disclose.
Assessment of Intervention by Palliative Care Team with Questionnaires
Authors: Hideaki Kawabata, Naoki Kakihara, Haruhiko Atsuta, Chiaki Taga, Masanori Nishikawa, Eiichiro Kanda, Yoko Nishimura, Yoko Nishitani, Miwa Sakuma, Mariko Nose
Journal: Annals of Oncology (2014)
Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.
Authors: Mairead G McNamara, John A. Bridgewater, Andre Lopes, Harpreet Wasan, David Malka, Henrik R Jensen, Takuji Okusaka, Jennifer J. Knox, Anna Dorothea Wagner, David Cunningham, Jenny Shannon, David Goldstein, Markus H. Moehler, Tanios S. Bekaii-Saab, Juan W. Valle
Journal: Journal of Clinical Oncology (2016)

382 Background: Outcomes in elderly patients (pts), with advanced biliary tract cancer (ABTC) receiving palliative chemotherapy are unclear. The aim of this study was to assess the outcome of monotherapy vs combination therapy in elderly pts with ABTC in ABC-02, and 10 other prospective studies of systemic therapy. Methods: Multivariable analysis was employed to explore impact of therapy on progression-free (PFS) and overall survival (OS) in 2 age cohorts; non-elderly ( &lt; 70 yrs) vs elderly ( ≥ 70 yrs). Results: Overall, 1163 pts were recruited from Jan 97-Dec 13. Median age of entire cohort was 63 yrs (range 23-85); 260 (22%) were ≥ 70 yrs, 18 (2%) were ≥ 80 yrs. In pts ≥ 70 yrs; 208 had ECOG PS 0-1, 129; male and 174; metastatic disease. Combination therapy was platinum-based in 9 studies. Among the 260 pts ≥ 70 yrs, 182 (70%) received combination therapy. Baseline characteristics/therapy received was balanced in both age cohorts. Median follow-up time for all pts was 42 months (95% CI 37-51). Median PFS for those &lt; 70 yrs and ≥ 70 yrs was 6.0 (95% CI 5.5-6.4) and 5.0 months (95% CI 4.2-6.4) respectively. Median OS for pts &lt; 70 yrs and ≥ 70 yrs was 10.2 (95% CI 9.6-11.1) and 8.8 months (95% CI 7.9-9.6) respectively. For the entire cohort, the PFS and OS were significantly better in those pts receiving combination therapy: HR 0.66, 95% CI 0.58-0.76, P &lt; 0.0001 and HR 0.72, 95% CI 0.63-0.82, P &lt; 0.0001 respectively, and in group ≥ 70 yrs: HR 0.54 (95% CI 0.38-0.77, P = 0.001) and HR 0.6 (95% CI 0.43-0.85, P = 0.004) respectively. In pts &lt; 70 yrs, stage (locally advanced vs metastatic) and ECOG PS were prognostic for PFS (P &lt; 0.001 and P = 0.04 respectively) and OS (P &lt; 0.001 and P = 0.001 respectively) and in pts ≥ 70 yrs, they were prognostic for OS (P = 0.03 and P = 0.02 respectively). There was no evidence of interaction between age ( &lt; 70 yrs and ≥ 70 yrs) and treatment (monotherapy and combination therapy) for PFS (P = 0.66) or OS (P = 0.75). Conclusions: In ABTC, PFS and OS in elderly pts receiving palliative chemotherapy (monotherapy or combination therapy) are comparable with that of non-elderly pts, therefore age in isolation should not influence treatment decisions. Clinical trial participation among elderly pts with ABTC is appropriate.
Fathers' smoking behaviors at home and near their children after a smoke-free legislation in Hong Kong : a two-group comparison
Authors: D.Y.P. Leung, S.S.C. Chan, Yim Wah Mak, G.M. Leung, T.H. Lam
Journal: Circulation (2010)

The World Congress of Cardiology: Scientific Sessions 2010. Beijing, China, 16-19 June, 2010
Multiple Myeloma: An Immunologic Profile. II. Bone Marrow Studies<xref ref-type="fn" rid="FN1">2</xref><xref ref-type="fn" rid="FN2">3</xref>
Authors: T Paglieroni, M R MacKenzie, V Caggiano
Journal: JNCI Journal of the National Cancer Institute (1978)

Bone marrow mononuclear cell populations were studied in 35 patients without myeloma, 39 patients with multiple myeloma, and 15 patients with benign monoclonal gammopathy. Bone marrow mononuclear cell receptors, responses to mitogens or allogeneic stimuli, and suppressive effects on in vitro peripheral blood lymphocyte (PBL) function were studied. In bone marrow cell populations from patients with untreated multiple myeloma, the percent of complement receptor-bearing cells and the pokeweed mitogen- and concanavalin A-stimulated responses were significantly greater than were those in bone marrow cell populations from patients without myeloma. Sheep red blood cell receptor-bearing cells were significantly greater in marrow populations from treated multiple myeloma patients compared to those from untreated multiple myeloma patients. Sheep red blood cell receptor-bearing cells from the bone marrow of multiple myeloma patients suppressed responses of the multiple myeloma patients' PBL's to autologous mitomycin C-treated bone marrow plasma cells and to allogeneic stimuli in one-way mixed leukocyte culture. Complement receptor-bearing cells suppressed the response to pokeweed mitogen. The presence of lymphocytes in the marrow compartment that are capable of suppressing the response of myeloma patients' PBL's to plasma cell antigens may be significant in the pathogenesis of multiple myeloma.
A lung cancer genomic risk prediction model derived from paraffin-embedded tissue
Authors: D. H. Harpole, M. M. Joshi, R. P. Petersen, D. H. Conlon, K. Tanaka, D. Shimizu, H. Kuramochi, M. Williams, P. V. Danenberg, K. Danenberg
Journal: Journal of Clinical Oncology (2006)

10059 Background: We previously developed a validated fresh tissue-based genomic risk model in patients with early stage non-small cell lung cancer (NSCLC) using the Affymetrix U133 plus 2.0 Genechip. Limitations of this fresh tissue-based model include the need for immediate processing and limited availability; however, formalin-fixed, paraffin-embedded (FFPE) tissue is readily available and archived on every patient resected in North America. We investigated the ability of gene expression profiles generated on DNA microarrays using RNA isolated from FFPE NSCLC specimens to distinguish short-term and long-term survivors. Methods: Five to ten 5 um sections of FFPE tumor were collected from 61 NSCLC patients consisting of equal numbers of long- (+5-year) and short-term (&lt;2 year cancer death) survivors. Fifty-five samples were microdissected (6 samples contained no tumor tissue) and RNA was extracted using a proprietary procedure of Response Genetics, Inc. For this feasibility study, Actin 300 &lt; 30 cTs was chosen as a threshold for adequate RNA quantity for amplification to the GeneChip. Amplification and labeling of RNA were done using the Affymetrix two cycle amplification kit. The resulting cRNA was successfully hybridized to the U133 plus 2.0 GeneChip in 54/55 samples (98%). Data were analyzed using the SAM statistical software with Kaplan Meier survival analyses. Results: All analyses were performed using unsupervised hierarchical clustering and blinded duplicate samples had nearly identical gene expression profiles, indicating reproducibility. Adenocarcinoma segregated from squamous cell carcinoma with 98% accuracy (p=0.00004). A differentially expressed gene list between long and short survivors was determined. Distinct gene clusters were observed within each histological type segregating the tumors according to outcome. Kaplan Meier survival analysis stratifying on these clusters revealed significant differences in survival (cluster 1 and cluster 2 median survival&gt;75 mos. vs. 30 mos., respectively; p&lt;0.001). Conclusions: We have demonstrated the feasibility of creating a preliminary genomic risk prediction model using FFPE NSCLC tissue. Data will be presented on a larger training set (100+ patients) and a separate validation cohort of 100 patients. [Table: see text]